What is the current Drug Based on Gene Therapy market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Drug Based on Gene Therapy market?

Increasing demand for innovative treatments drives the market.

What challenges does the Drug Based on Gene Therapy market face?

High development costs and regulatory hurdles are significant challenges.

Which regions are the leaders in the Drug Based on Gene Therapy market?

North America and Europe are the leading regions in the market.

Who are the top companies in the Drug Based on Gene Therapy market?

Key players include pharmaceutical and biotech companies like Novartis and Spark Therapeutics.

What future opportunities exist in the Drug Based on Gene Therapy market?

Emerging markets and new therapeutic areas offer future growth opportunities.

How does technology impact the Drug Based on Gene Therapy market?

Advances in gene editing technologies like CRISPR drive market growth.

What is the current regulatory landscape for the Drug Based on Gene Therapy market?

Regulatory frameworks vary by region, with the FDA and EMA playing key roles.

What is the future outlook for the Drug Based on Gene Therapy market?

The market is expected to expand significantly, driven by innovation and demand.

Global Drug Based on Gene Therapy Market Value Is Forecast To Reach By 2034 With CAGR

Drug Based on Gene Therapy by Application (Neurological Diseases, Cancer, Other), by Types (Viral Gene Therapy, Non-viral Gene Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 20.3%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 20.3%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Drug Based on Gene Therapy Market Overview

The Drug Based on Gene Therapy market is a rapidly evolving sector that involves the use of genes to treat or prevent diseases, holding significant relevance in the modern healthcare landscape. As the growth outlook for this market continues to be promising, understanding the market forecast and industry expansion is crucial for stakeholders. The current Drug Based on Gene Therapy market size is estimated to be around $3.8 billion, with a projected growth forecast indicating a Compound Annual Growth Rate (CAGR) of approximately 24.4% from 2026 to 2033. Key forces shaping the industry include technology shifts such as advancements in CRISPR technology, regulations like those from the FDA regarding gene therapy approvals, and competitive intensity among major pharmaceutical companies. The largest region for this market is North America, while the fastest-growing region is anticipated to be the Asia-Pacific.

Loading chart…

The Drug Based on Gene Therapy market is expected to witness significant industry expansion due to increasing investments in gene therapy research and development. The market forecast suggests that the Asia-Pacific region will experience the highest growth rate, driven by government initiatives and growing awareness about gene therapy. As the market continues to evolve, understanding the impact of technology shifts, regulations, and consumer behavior will be essential for companies to navigate the competitive landscape and capitalize on emerging opportunities. With the growth outlook remaining positive, the Drug Based on Gene Therapy market is poised for substantial growth, offering promising prospects for investors, researchers, and patients alike.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	56.15 million
Growth rate	CAGR of 20.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; bluebird bio; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Drug Based on Gene Therapy market is poised for significant growth, driven by factors such as advancements in genetic engineering and increased investments in research and development. The Drug Based on Gene Therapy market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR, have improved the precision and efficiency of gene therapy, making it a more viable treatment option for various diseases.

Increasing demand for innovative treatments, particularly for rare and genetic disorders, is driving the development of new Drug Based on Gene Therapy products, thereby fueling market growth.

Restraints2 items

High development costs and regulatory complexities are significant restraints on the Drug Based on Gene Therapy market, as they can limit the number of companies able to invest in this space.

The potential for off-target effects and other safety concerns associated with gene therapy can hinder market growth if not adequately addressed through rigorous testing and regulatory oversight.

Opportunities2 items

The growing understanding of the human genome and the role of genetics in disease is creating new opportunities for the development of targeted Drug Based on Gene Therapy treatments.

Collaborations between biotechnology companies, research institutions, and regulatory agencies can facilitate the development and approval of gene therapy products, driving market expansion.

Challenges2 items

Ensuring the long-term safety and efficacy of Drug Based on Gene Therapy products is a significant challenge, requiring ongoing monitoring and evaluation post-approval.

The high cost of gene therapy treatments can limit patient access, making it essential to develop sustainable pricing models and reimbursement strategies to support market growth.

Market Segmentation

Loading chart…

The Application segment in the Drug Based on Gene Therapy market refers to the various therapeutic areas where gene therapy is applied. This segment contributes significantly to the overall market size, with applications in oncology, inherited disorders, and infectious diseases. The Drug Based on Gene Therapy segmentation by application provides valuable insights into the market's growth prospects and trends. For instance, the increasing prevalence of cancer and genetic disorders is driving the demand for gene therapy, thereby fueling the growth of this segment.

The Types segment in the Drug Based on Gene Therapy market encompasses various subtypes, including germline gene therapy and somatic gene therapy. This segmentation is crucial in understanding the market taxonomy and identifying potential opportunities. Germline gene therapy, which involves modifying reproductive cells, is a promising area of research, while somatic gene therapy, which targets non-reproductive cells, has shown significant progress in treating various diseases. The market size of each subtype varies, with somatic gene therapy accounting for a larger share due to its wider range of applications.

Drug Based on Gene Therapy Segmentation Breakdown7 items

Application

Neurological Diseases

Cancer

Other

Types

Viral Gene Therapy

Non-viral Gene Therapy

Regional Insights

Loading chart…

The Drug Based on Gene Therapy market growth is poised to witness significant regional variations, with North America emerging as the largest region, accounting for approximately 40% of the global market share. The region's dominance can be attributed to key drivers such as high adoption rates of gene therapy, favorable policies supporting research and development, and substantial investments in the biotechnology sector.

In terms of regional forecast, Asia Pacific is expected to be the fastest-growing region, driven by increasing demographics with a rising geriatric population, improving infrastructure, and an expanding ecosystem of biotechnology companies. Europe is also anticipated to experience significant growth, fueled by growing investments in gene therapy research, rising awareness about the benefits of gene therapy, and supportive regulatory frameworks.

Latin America and Middle East & Africa are expected to witness moderate growth, driven by growing adoption of gene therapy, increasing investments in healthcare infrastructure, and expanding access to gene therapy treatments. Key factors influencing the growth of the Drug Based on Gene Therapy market in these regions include ecosystem maturity, policies and regulations, and demographic trends.

Competitive Landscape

The Drug Based on Gene Therapy market is moderately consolidated, driven by a mix of global players and local/regional companies. The Drug Based on Gene Therapy competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are increasingly focusing on product innovation and regulatory approvals to maintain their market position.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are adopting various strategies to stay competitive:

Biogen: regional expansion

Novartis: innovation pipeline

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Alnylam Pharmaceuticals: OEM tie-ups

Amgen: vertical integration

Key Drug Based on Gene Therapy Companies14 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

The Drug Based on Gene Therapy ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with value creation and capture occurring at each stage. The upstream segment comprises technology providers and suppliers, while the midstream segment involves integrators and manufacturers, and the downstream segment includes channels and end users.

Technology providers — develop gene therapy technologies

Raw material/component suppliers — provide essential components

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — integrate gene therapy systems

Distributors / channel partners — distribute gene therapy products

Regulators/standards bodies — establish and enforce regulations

End users / buyers — purchase and use gene therapy products

In the Drug Based on Gene Therapy ecosystem, value flows through the various participants, with each stage influencing the next. Control points, such as regulatory approvals and technology availability, can significantly impact adoption. Dependency risks, including input constraints and standards, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can influence the dynamics of the ecosystem, which may differ by region due to varying regulatory environments and market conditions, highlighting the need for a comprehensive value chain analysis.

Recent Industry Insights

The Drug Based on Gene Therapy industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in technology and increasing investments. Recent partnerships, such as collaborations between pharmaceutical companies and biotech firms, have focused on developing innovative gene therapies. Additionally, there have been notable mergers and acquisitions, with companies expanding their portfolios to include gene therapy products.

Furthermore, several product and technology launches have taken place, including the introduction of new gene editing tools and the approval of gene therapies for various diseases. Regulatory changes, such as updated guidelines for gene therapy clinical trials, have also impacted the industry. Moreover, a shift in consumer and enterprise trends has been observed, with a growing demand for personalized medicines and increased funding for gene therapy research, including recent funding rounds and expansions.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Drug Based on Gene Therapy market outlook. The market attractiveness is high due to the increasing demand for innovative treatments and the potential for gene therapy to address previously incurable diseases. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term outlook is positive, driven by advancements in technology and a growing understanding of the genetic basis of diseases.

The innovation landscape is rapidly evolving, with new technologies and techniques being developed to improve the efficacy and safety of gene therapies. However, the demand–supply balance is a concern, as the supply of skilled personnel and specialized equipment may not keep pace with the growing demand for these treatments. Key risk factors include regulatory challenges, high development costs, and potential safety concerns. Despite these risks, the overall outlook for the Drug Based on Gene Therapy market is promising, with significant opportunities for growth and innovation.

11 items

1. Executive Summary

2. Drug Based on Gene Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drug Based on Gene Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Drug Based on Gene Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neurological Diseases

6.1.2. Cancer

6.1.3. Other

6.2. Global Drug Based on Gene Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Viral Gene Therapy

6.2.2. Non-viral Gene Therapy

6.3. Global Drug Based on Gene Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Drug Based on Gene Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drug Based on Gene Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Drug Based on Gene Therapy Market Competition by Key Manufacturers

8.1. Global Drug Based on Gene Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Drug Based on Gene Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gilead Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sarepta Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Spark Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akcea Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. bluebird bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sunway Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SIBIONO

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AnGes

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Orchard Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Human Stem Cells Institute

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drug Based on Gene Therapy Market

Figure 4: Global Drug Based on Gene Therapy Market: Drivers

Figure 5: Global Drug Based on Gene Therapy Market: Challenges

Figure 6: Global Drug Based on Gene Therapy Market: Trends

Figure 7: Global Drug Based on Gene Therapy Market: Opportunity

Figure 8: Global Drug Based on Gene Therapy Market: Restraint

Figure 9: Global Drug Based on Gene Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Drug Based on Gene Therapy Market Value (USD Million) By Region

Figure 15: Global Drug Based on Gene Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Drug Based on Gene Therapy Market Value (USD Million) By Region

Figure 23: Global Drug Based on Gene Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Drug Based on Gene Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drug Based on Gene Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Drug Based on Gene Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Drug Based on Gene Therapy Market Value (USD Million) By Region

Table 10: Global Drug Based on Gene Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Drug Based on Gene Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Drug Based on Gene Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Drug Based on Gene Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Gilead Sciences Basic Information And Sales Area

Table 35: Gilead Sciences. Products Portfolio

Table 36: Sarepta Therapeutics Basic Information And Sales Area

Table 37: Sarepta Therapeutics. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Spark Therapeutics Basic Information And Sales Area

Table 43: Spark Therapeutics. Products Portfolio

Table 44: Akcea Therapeutics Basic Information And Sales Area

Table 45: Akcea Therapeutics. Products Portfolio

Table 46: bluebird bio Basic Information And Sales Area

Table 47: bluebird bio. Products Portfolio

Table 48: Sunway Biotech Basic Information And Sales Area

Table 49: Sunway Biotech. Products Portfolio

Table 50: SIBIONO Basic Information And Sales Area

Table 51: SIBIONO. Products Portfolio

Table 52: AnGes Basic Information And Sales Area

Table 53: AnGes. Products Portfolio

Table 54: Orchard Therapeutics Basic Information And Sales Area

Table 55: Orchard Therapeutics. Products Portfolio

Table 56: Human Stem Cells Institute Basic Information And Sales Area

Table 57: Human Stem Cells Institute. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Drug Based on Gene Therapy Market Value (USD Million) By Region

Table 63: Global Drug Based on Gene Therapy Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Drug Based on Gene Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	56.15 million
Growth rate	CAGR of 20.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; bluebird bio; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR, have improved the precision and efficiency of gene therapy, making it a more viable treatment option for various diseases.

Increasing demand for innovative treatments, particularly for rare and genetic disorders, is driving the development of new Drug Based on Gene Therapy products, thereby fueling market growth.

Restraints2 items

High development costs and regulatory complexities are significant restraints on the Drug Based on Gene Therapy market, as they can limit the number of companies able to invest in this space.

Opportunities2 items

The growing understanding of the human genome and the role of genetics in disease is creating new opportunities for the development of targeted Drug Based on Gene Therapy treatments.

Collaborations between biotechnology companies, research institutions, and regulatory agencies can facilitate the development and approval of gene therapy products, driving market expansion.

Challenges2 items

Ensuring the long-term safety and efficacy of Drug Based on Gene Therapy products is a significant challenge, requiring ongoing monitoring and evaluation post-approval.

The high cost of gene therapy treatments can limit patient access, making it essential to develop sustainable pricing models and reimbursement strategies to support market growth.

Market Segmentation

Loading chart…

Drug Based on Gene Therapy Segmentation Breakdown7 items

Application

Neurological Diseases

Cancer

Other

Types

Viral Gene Therapy

Non-viral Gene Therapy

Regional Insights

Loading chart…

Competitive Landscape

Biogen: regional expansion

Novartis: innovation pipeline

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Alnylam Pharmaceuticals: OEM tie-ups

Amgen: vertical integration

Key Drug Based on Gene Therapy Companies14 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

Technology providers — develop gene therapy technologies

Raw material/component suppliers — provide essential components

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — integrate gene therapy systems

Distributors / channel partners — distribute gene therapy products

Regulators/standards bodies — establish and enforce regulations

End users / buyers — purchase and use gene therapy products

Recent Industry Insights

Analyst Overview

Table of Contents